Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Lack of Utility of CD20 Immunohistochemistry in Staging Bone Marrow Biopsies for Diffuse Large B-cell Lymphoma

Lack of Utility of CD20 Immunohistochemistry in Staging Bone Marrow Biopsies for Diffuse Large... RESEARCH ARTICLE Lack of Utility of CD20 Immunohistochemistry in Staging Bone Marrow Biopsies for Diffuse Large B-cell Lymphoma Daniel Baiyee, MD, Roger Warnke, MD, and Yasodha Natkunam, MD, PhD marrow evaluation, immunohistochemistry can be a Abstract: The utility of CD20 immunohistochemistry in the useful adjunct for the assessment of the extent of bone evaluation of staging bone marrow biopsies of newly diagnosed marrow involvement, especially in cases with minimal 8–10 diffuse large B-cell lymphoma (DLBCL) patients has not been infiltration or discordant morphology. Moreover, extensively studied. We used 113 routinely processed bone decalcification and processing may compromise optimal marrow biopsies to study the extent and pattern of involvement histologic preservation making morphologic interpreta- by lymphoma and CD20 staining. Twelve (10.6%) of 113 cases tion challenging in some instances. In this study, we had involvement by morphology, and 5 (41.7%) of these showed evaluated the usefulness of immunohistochemistry for histologic discordance between the primary site and the bone CD20 in identifying bone marrow involvement by newly marrow. All cases with morphologic evidence of bone marrow diagnosed DLBCL. involvement showed staining for CD20. Four (3.5%) of 113 cases had non-neoplastic aggregates that stained for CD20. One MATHERIALS AND METHODS case (0.9%) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Lack of Utility of CD20 Immunohistochemistry in Staging Bone Marrow Biopsies for Diffuse Large B-cell Lymphoma

Download PDF
3 pages

Loading next page...
 
/lp/wolters-kluwer-health/lack-of-utility-of-cd20-immunohistochemistry-in-staging-bone-marrow-ETVZ7rpGJ0

References (18)

ISSN
1541-2016
eISSN
1533-4058
DOI
10.1097/PAI.0b013e318184cd3f
pmid
19521275
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE Lack of Utility of CD20 Immunohistochemistry in Staging Bone Marrow Biopsies for Diffuse Large B-cell Lymphoma Daniel Baiyee, MD, Roger Warnke, MD, and Yasodha Natkunam, MD, PhD marrow evaluation, immunohistochemistry can be a Abstract: The utility of CD20 immunohistochemistry in the useful adjunct for the assessment of the extent of bone evaluation of staging bone marrow biopsies of newly diagnosed marrow involvement, especially in cases with minimal 8–10 diffuse large B-cell lymphoma (DLBCL) patients has not been infiltration or discordant morphology. Moreover, extensively studied. We used 113 routinely processed bone decalcification and processing may compromise optimal marrow biopsies to study the extent and pattern of involvement histologic preservation making morphologic interpreta- by lymphoma and CD20 staining. Twelve (10.6%) of 113 cases tion challenging in some instances. In this study, we had involvement by morphology, and 5 (41.7%) of these showed evaluated the usefulness of immunohistochemistry for histologic discordance between the primary site and the bone CD20 in identifying bone marrow involvement by newly marrow. All cases with morphologic evidence of bone marrow diagnosed DLBCL. involvement showed staining for CD20. Four (3.5%) of 113 cases had non-neoplastic aggregates that stained for CD20. One MATHERIALS AND METHODS case (0.9%)

Journal

Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health

Published: Mar 1, 2009

There are no references for this article.